SLC5A2 and type 2 diabetes mellitus: This meta-analysis confirmed that SGLT-2 inhibitors reduced BW, BMI, WC, VFA, SFA, PBF, FM, LM and SMM to a greater extent than other hypoglycemic agents in T2DM.